Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

Abstract

Abstract. Barter PJ, Ballantyne CM, Carmena R,

Ezetimibe: cholesterol lowering and beyond

“…Similar to non-HDL-C, it has been suggested that measurement of plasma ApoB levels is a better predictor of CHD risk than LDL-C [86][87][88][89] and concentrations less than 90 mg/dl may be considered an alternative secondary target for high-risk patients by the ATP III and CMA/Canadian guidelines [74,90]. Non-HDL-C atherogenic lipoproteins contain ApoB, and both measurements correlate to increased CHD risk [72,86], although the concordance of this in various population distributions remains unclear [87,91].…”

“…Similar to non-HDL-C, it has been suggested that measurement of plasma ApoB levels is a better predictor of CHD risk than LDL-C [86][87][88][89] and concentrations less than 90 mg/dl may be considered an alternative secondary target for high-risk patients by the ATP III and CMA/Canadian guidelines [74,90]. Non-HDL-C atherogenic lipoproteins contain ApoB, and both measurements correlate to increased CHD risk [72,86], although the concordance of this in various population distributions remains unclear [87,91]. Measurement of ApoB is thought by some to provide a more accurate assessment of lipoprotein atherogenicity than non-HDL-C [86][87][88][89] because unlike non-HDL-C, which measures the cholesterol content of particles, ApoB provides a direct assessment of atherogenic particle number.…”

“…Non-HDL-C atherogenic lipoproteins contain ApoB, and both measurements correlate to increased CHD risk [72,86], although the concordance of this in various population distributions remains unclear [87,91]. Measurement of ApoB is thought by some to provide a more accurate assessment of lipoprotein atherogenicity than non-HDL-C [86][87][88][89] because unlike non-HDL-C, which measures the cholesterol content of particles, ApoB provides a direct assessment of atherogenic particle number. Particle number is thought to be an important determinant of atherogenic burden and CHD risk, although the association of particle size and composition with CHD risk remains controversial [72,86,88,89].…”

“…Measurement of ApoB is thought by some to provide a more accurate assessment of lipoprotein atherogenicity than non-HDL-C [86][87][88][89] because unlike non-HDL-C, which measures the cholesterol content of particles, ApoB provides a direct assessment of atherogenic particle number. Particle number is thought to be an important determinant of atherogenic burden and CHD risk, although the association of particle size and composition with CHD risk remains controversial [72,86,88,89]. Chylomicron particles contain 1 molecule of ApoB-48, and VLDL, IDL and LDL-C particles contain one molecule each of ApoB-100.…”

“…As the majority of the total ApoB-containing lipoproteins in the plasma are associated with LDL particles, measurement of ApoB primarily reflects ApoB-100 levels [86]. Similar to non-HDL-C, it has been suggested that measurement of plasma ApoB levels is a better predictor of CHD risk than LDL-C [86][87][88][89] and concentrations less than 90 mg/dl may be considered an alternative secondary target for high-risk patients by the ATP III and CMA/Canadian guidelines [74,90].…”